Regeneron Pharmaceuticals Stock News

The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by over 1.4% pre-market today. This is why it happened.

New Jersey, United States,- Verified Market Research has recently published a research report titled, Rheumatoid Arthritis Therapeutics Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

(RTTNews) - Phase 3 results showed that adding Dupixent or dupilumab to standard-of-care topical corticosteroids significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis, Regeneron Pharmaceuticals Inc.

Janney Montgomery Scott LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 26,733 shares of the biopharmaceutical companys stock after buying an additional 813 shares during the quarter. Janney Montgomery Scott LLCs holdings in []

Harel Insurance Investments & Financial Services Ltd. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 83.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 372 shares of the biopharmaceutical companys stock after selling 1,861 shares during the quarter. Harel Insurance Investments []

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Marc Tessier-Lavigne sold 3,784 shares of the companys stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $665.00, for a total value of $2,516,360.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Shares of []

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Andrew J. Murphy sold 7,122 shares of the businesss stock in a transaction dated Friday, December 10th. The stock was sold at an average price of $666.27, for a total value of $4,745,174.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available []

Related Stocks: REGN ,

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said that results from the Phase 1 portion of the Phase 1/2 trial in patients with relapsed/refractory multiple myeloma found a 51% overall response rate across all dose groups, rising to 75% in patients who received higher doses of REGN5458 (200-800 mg). REGN5458 is a bispecific antibody

Strs Ohio trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the third quarter, Holdings Channel reports. The firm owned 45,404 shares of the biopharmaceutical companys stock after selling 3,069 shares during the quarter. Strs Ohios holdings in Regeneron Pharmaceuticals were worth $27,477,000 as of its most recent filing with the []

Related Stocks: FB , IBM , ATH , REGN , ZD , WMT , BX , HSY , EVRG , EXPD , SBUX , DOV , LOW , KLAC , DTE , PEG , DE , MCD ,

Related Stocks: REGN ,

Sumitomo Mitsui Trust Holdings Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% in the third quarter, HoldingsChannel.com reports. The firm owned 469,269 shares of the biopharmaceutical company’s stock after selling 82,083 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Regeneron Pharmaceuticals were worth $283,992,000 at the end […]

Cowen initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note released on Tuesday, FinViz reports. The firm issued a market perform rating and a $625.00 price objective on the biopharmaceutical companys stock. A number of other equities analysts also recently weighed in on REGN. SVB Leerink boosted their price target on shares []